jhavlek

About Jennifer Havlek

This author has not yet filled in any details.
So far Jennifer Havlek has created 34 blog entries.
10 Dec, 2018

2018 SITC: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoepitope Burden and Tumor Escape Mechanisms for Clinical Treatment

2018 SITC: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoepitope Burden and Tumor Escape Mechanisms for Clinical Treatment Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. It is of great interest to identify biomarkers and mechanisms that [...]

10 Dec, 2018

2018 SITC: Improving Neoantigen Identication for Therapeutic and Diagnostic Use in Immuno-oncology Using Mass Spectrometry and Machine Learning

2018 SITC: Improving Neoantigen Identification for Therapeutic and Diagnostic Use in Immuno-Oncology Using Mass Spectrometry and Machine Learning Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune [...]

10 Dec, 2018

2018 AACR: Methods of Improving Accuracy of Neoantigen Identication for Therapeutic and Diagnostic Use in Immuno-oncology

2018 AACR: Methods of Improving Accuracy of Neoantigen Identication for Therapeutic and Diagnostic Use in Immuno-oncology Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. However, the methods for identifying which neoepitopes are more likely to provoke an immune response remains [...]

10 Dec, 2018

2018 AACR: Supporting Neoantigen Discovery and Monitoring in Plasma Through Analytical Validation of a Deep Augmented Content Enhanced (ACE) Exome

2018 AACR: Supporting Neoantigen Discovery and Monitoring in Plasma Through Analytical Validation of a Deep Augmented Content Enhanced (ACE) Exome Neoantigens are increasingly critical in immuno-oncology as a therapeutic target for neoantigen-based personalized cancer vaccines and as a potential biomarker for immunotherapy response. An important step in identifying neoantigens is comprehensive exome and transcriptome [...]

10 Dec, 2018

2018 AACR: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoantigen Burden and Tumor Escape Mechanisms for Clinical Treatment

2018 AACR: Molecular Profiling of Anti-PD-1 Treated Melanoma Patients Reveals Importance of Assessing Neoantigen Burden and Tumor Escape Mechanisms for Clinical Treatment Despite the remarkable response of some melanoma patients to checkpoint inhibitor therapy, significant numbers of patients do not achieve complete response. To understand this differential response, there is an increasing interest in [...]

10 Dec, 2018

2018 AACR: Deconvolution of Diverse Immune Cell Populations within Tumors using ACE Transcriptome

2018 AACR: Deconvolution of diverse immune cell populations within tumors using ACE Transcriptome Comprehensive tumor immuno-genomic characterization is becoming an important tool for identifying new biomarkers correlated with patient response to immunotherapy. Both the abundance and composition of tumor-infiltrating immune cells have been associated with tumor progression and patient outcome. There is interest in [...]

27 Nov, 2018

Personalis to Present at the 4th Annual ICI Europe Summit 2018 in Berlin

Personalis, Inc. to Present at the 4th Annual ICI Europe Summit 2018 in Berlin Menlo Park, CA – November 27, 2018 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming ICI Europe Summit 2018 in Berlin, Germany on Wednesday, November 28, 2018 [...]

14 Nov, 2018

Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston

Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston Menlo Park, CA – November 14, 2018 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming NeoAG Summit in Boston, MA on Thursday, November 15, 2018 at 4:00 [...]

9 Nov, 2018

Personalis Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and its Microenvironment from a Single Sample

Personalis, Inc. Launches ImmunoID NeXT, the First Platform Providing Characterization of a Tumor and its Microenvironment from a Single Sample Menlo Park, CA – November 9, 2018 – Personalis, Inc., a leader in advanced genomics for precision oncology, today announced the launch of its universal cancer immunogenomics platform, ImmunoID NeXT™. This is the first platform [...]